SCHEMBL5367073

SCHEMBL5367073

Cc1ccc(Cc2ccc(=O)[nH]n2)cc1Oc1ccccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.44
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 2/20 0.37
SLC6A3 Q01959 2/20 0.37
ADORA2A P29274 1/20 0.35
AKR1B1 P15121 2/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
CYP2C19 P33261 1/20 0.34
CAMK2A Q9UQM7 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HTT P42858 1/20 0.34
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
PARP1 P09874 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5374337 0.91 CYP3A4 (0.47) CYP3A4SLC6A2SLC6A4SLC6A3AKR1B1
SCHEMBL5373719 0.88 CYP3A4 (0.46) CYP3A4SLC6A4ADORA2AAKR1B1KDM4E
SCHEMBL5374344 0.88 CYP3A4 (0.43) CYP3A4SLC6A2SLC6A4SLC6A3AKR1B1
SCHEMBL5377719 0.86 CYP3A4 (0.46) CYP3A4SLC6A2SLC6A4SLC6A3AKR1B1
SCHEMBL5370985 0.85 CYP3A4 (0.48) CYP3A4ADORA2ACYP2C9TSHRCYP2C19
SCHEMBL5374946 0.84 CYP3A4 (0.42) CYP3A4AKR1B1CAMK2APRMT5WDR77
SCHEMBL14559753 0.83 AR (0.39) CYP3A4SLC6A4SLC6A3CYP2C9CYP2C19
SCHEMBL5365171 0.83 CYP3A4 (0.49) CYP3A4SLC6A4KDM4ENPC1RAB9A
SCHEMBL5368939 0.82 CYP3A4 (0.64) CYP3A4SLC6A2SLC6A4SLC6A3AKR1B1
SCHEMBL5373947 0.82 CYP3A4 (0.44) CYP3A4AKR1B1CYP2C9TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189718-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-03-13 US disclosed
US-7189718-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-03-13 US disclosed
US-7189718-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-03-13 US disclosed
EP-1608629-A1 BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-28 EP disclosed
US-20040198736-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2004-10-07 US disclosed
WO-2004085406-A1 BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198736-A1 Non-nucleoside reverse transcriptase inhibitors POLR1A, POLR2A, POLR2E CYP3A4 264/4885SLC6A2 3490/4885SLC6A4 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.